| Appearance: | Solid powder |
| Purity: | 98% |
| Cat No: | A000505 |
| Cas No: | 79794-75-5 |
| Product-Name: | Loratadine |
| IUPAC Name: | ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate |
| InChI: | InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3 |
| InChIKey: | JCCNYMKQOSZNPW-UHFFFAOYSA-N |
| SMILES: | CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1 |
Loratadine(CAS 79794-75-5) is a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria.
Loratadine is a Histamine H1 receptor antagonist developed by the NovaDel Pharma.The Phase-II for Seasonal allergic rhinitis in USA (Transmucosal) was suspended in 2004.
1: Kay GG, Harris AG. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin Exp Allergy. 1999 Jul;29 Suppl 3:147-50. Review. PubMed PMID: 10444229.
2: Monroe EW. Safety and efficacy of loratadine in urticaria. Int J Dermatol. 1996 Dec;35(12):837-41. Review. PubMed PMID: 8970837.
3: Clissold SP, Sorkin EM, Goa KL. Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1989 Jan;37(1):42-57. Review. PubMed PMID: 2523301.
Your information is safe with us.